Targeted Strategies for Today's Evolving Markets

MissionIR Blog

ImmunoCellular Therapeutics, Ltd. (IMUC) Starts Presentation at 2015 Marcum MicroCap Conference

ImmunoCellular Therapeutics, a clinical-stage biotechnology company based in Calabasas, California, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidates includes ICT-107, a dendritic cell (DC) vaccine that completed phase 2 testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers; and ICT-140 for ovarian cancer. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. For more information, visit the company’s website at

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.